{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:45:37Z","timestamp":1782535537459,"version":"3.54.5"},"reference-count":18,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    Background: Buprenorphine is an opioid that has recently gained interest for acute pain management in post-operative patients. It has theoretical advantages due to its unique mechanism and favorable adverse effect profile. Currently, no studies have evaluated intravenous buprenorphine for acute pain management in a critically ill medical patient population. Objective: The objective of this study was to compare the use of intravenous buprenorphine with or without a full agonist IV opioid vs a full agonist IV opioid alone for acute pain in non-ventilated, non-surgical critically ill patients. Methods: A retrospective cohort study was completed of patients who received IV buprenorphine or full-agonist opioids while admitted to the medical intensive care unit at an academic medical center and community hospital. Results: The median DVPRS difference in the buprenorphine group compared to the control group was 5 vs 6. The non-inferiority t-test showed buprenorphine was not significantly non-inferior with mean DVPRS score at day 3 for the buprenorphine group was 5.02 and the control group was 5.07 (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.85). Respiratory depression within 7 days occurred less in the buprenorphine group (20.6% vs 42.9%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.004). Oversedation occurred less in the buprenorphine group (27% vs 46.8%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.01. The ICU LOS was longer in the buprenorphine group (8 vs 5 days,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.01). The median daily OME on day 1 was less in the buprenorphine group (29 vs 42.5,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.03). Conclusion: Intravenous buprenorphine may be a comparable alternative to full agonist intravenous opioids for pain control in the medical intensive care unit.\n                  <\/jats:p>","DOI":"10.1177\/08971900251384153","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:21:23Z","timestamp":1759278083000},"page":"271-279","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Intravenous Buprenorphine for Acute Pain in Critically Ill Patients in a Medical Intensive Care Unit"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0177-8646","authenticated-orcid":false,"given":"Kennedi","family":"Satterfield","sequence":"first","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Elefritz","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Quirk","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennica","family":"Johns","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ehrman","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9540-1701","authenticated-orcid":false,"given":"Brookeanne","family":"Magrum","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2015.03.021"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003299"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000263034.96885.e1"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06115-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2022.0399"},{"key":"e_1_3_3_7_2","volume-title":"North Chesterfield","author":"Buprenex (buprenorphine) injection [prescribing information]","year":"2022","unstructured":"Buprenex (buprenorphine) injection [prescribing information]. North Chesterfield. VA: Indivior Inc; 2022."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2017.11.086"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1800222"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000665"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000006031"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aex174"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)33306-9"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1980.tb01584.x"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.71"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000006052"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251384153","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251384153","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251384153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:56:27Z","timestamp":1782532587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251384153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1177\/08971900251384153"],"URL":"https:\/\/doi.org\/10.1177\/08971900251384153","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}